Reuters logo
Alkermes' schizophrenia drug meets main goal of late-stage study
April 8, 2014 / 11:10 AM / 4 years ago

Alkermes' schizophrenia drug meets main goal of late-stage study

April 8 (Reuters) - Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study.

The company said it planned to submit a marketing approval application for the drug, aripiprazole lauroxil, to the U.S. Food and Drug Administration in the third quarter of 2014. (Reporting by Vrinda Manocha in Bangalore; Editing by Savio D‘Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below